CDC25C as a Predictive Biomarker for Immune Checkpoint Inhibitors in Patients With Lung Adenocarcinoma

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Immune checkpoint inhibitors (ICIs) have improved survival in non-small cell lung cancer (NSCLC).
• However, many patients do not respond to ICIs or develop resistance, necessitating new biomarkers.
• Predictive biomarkers for ICI efficacy and resistance mechanisms are crucial for NSCLC treatment.

Purpose of the Study:

• To investigate the role of cell division cycle 25C (CDC25C) as a potential biomarker in lung adenocarcinoma (LUAD).
• To assess the association between CDC25C expression and patient survival, ICI treatment response, and the tumor microenvironment.

Main Methods:

• Analysis of CDC25C expression in LUAD using multiple databases and quantitative PCR (q-PCR).
• Correlation of CDC25C expression with overall survival, pathological stage, and progression-free survival in patients treated with nivolumab.
• Investigation of the relationship between CDC25C expression, immune cell infiltration, and immune-related signatures in the LUAD tumor microenvironment.

Main Results:

• CDC25C expression was upregulated in LUAD compared to normal lung tissue.
• Higher CDC25C expression correlated with shorter overall survival, worse pathological stage, and shorter progression-free survival in LUAD patients receiving nivolumab.
• CDC25C expression was significantly associated with immune cell infiltration and immune signatures within the LUAD tumor microenvironment.
• CDC25C demonstrated differential expression and prognostic value across multiple tumor types, suggesting broad applicability.

Conclusions:

• CDC25C serves as a prognostic biomarker for LUAD patients, particularly those undergoing ICI therapy.
• The study highlights the involvement of the cell cycle in ICI therapy efficacy and the tumor microenvironment.
• CDC25C is a potential broad-spectrum biomarker for predicting patient outcomes in various cancers.